AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Discover key takeaways from Surgery Partners' Q4 2024 earnings call, including strong revenue growth, strategic M&A, and 2025 guidance with robust ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Technology and Consumer Discretionary are the only two sectors down in the first two months of this year, among the 11 market ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...